Core Points - A shareholder class action lawsuit has been filed against Navan, Inc. alleging false and misleading statements regarding the company's business and operations [1] - The lawsuit specifically highlights that Navan increased its "sales and marketing" expenses by 39% for the quarter ending October 31, 2025, coinciding with its initial public offering [1] Legal Information - Investors who purchased Navan shares during the October 31, 2025 IPO and suffered significant losses are encouraged to discuss their legal rights with the law firm Holzer & Holzer [2] - The deadline to request lead plaintiff status in the lawsuit is April 24, 2026 [3]

Core Viewpoint - A shareholder class action lawsuit has been filed against Paysafe Limited, alleging false and misleading statements regarding the company's business and financial health [1] Group 1: Allegations in the Lawsuit - The lawsuit claims that Paysafe's ecommerce business had significant exposure to a single high-risk client [1] - It is alleged that the company's credit loss reserves and/or write-offs were understated due to this exposure [1] - The lawsuit points out that Paysafe had undisclosed issues with higher risk Merchant Category Codes, complicating its client services [1] - These issues are expected to have a material negative impact on the company's revenue growth and overall revenue mix [1] - As a result of these factors, Paysafe is unlikely to meet its previously issued financial guidance for fiscal year 2025 [1] Group 2: Legal Information - Investors who purchased Paysafe shares between March 4, 2025, and November 12, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed lead plaintiff in the case is April 7, 2026 [3] - Holzer & Holzer, LLC is a law firm specializing in shareholder class action and derivative litigation, having recovered hundreds of millions for shareholders affected by corporate misconduct [3]

ATLANTA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Varonis Systems, Inc. (NASDAQ: VRNS). The lawsuit alleges that Defendants issued false and misleading statements concerning Varonis’ ability to convert its existing customer base and its ARR growth potential in the near-term. If you purchased Varonis shares between February 4, 2025 and October 28, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by ...

Core Viewpoint - A shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, alleging false and misleading statements regarding the company's business and operations, particularly concerning the CELLECTRA device and the INO-3107 Biologics License Application [1] Group 1: Allegations in the Lawsuit - The lawsuit claims that Inovio's manufacturing for the CELLECTRA device was deficient [1] - It is alleged that Inovio is unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 [1] - The company reportedly lacks sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [1] - Consequently, the overall regulatory and commercial prospects of INO-3107 are claimed to be overstated [1]

ATLANTA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) Pomdoctor was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (ii) insiders and/or affiliates used of ...

ATLANTA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Ultragenyx’s expected results for its Phase III Orbit and Cosmic Studies, including setrusumab’s potential and the risks inherent in the study protocols put forth. If you purchased Ultragenyx shares ...

ATLANTA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that Defendants concealed and misrepresented facts regarding setrusumab’s ability to achieve statistical significance for the primary endpoints in both the ORBIT and COSMIC studies. If you purcha ...

Core Viewpoint - A shareholder class action lawsuit has been filed against Plug Power Inc. alleging false and misleading statements regarding the company's business and operations, particularly concerning the Department of Energy Loan and the construction of hydrogen production facilities [1] Group 1: Allegations - The lawsuit claims that defendants overstated the likelihood of funds from the Department of Energy Loan becoming available to Plug Power [1] - It is alleged that Plug Power may pivot towards more modest projects with less commercial upside due to these misrepresentations [1] Group 2: Legal Information - Shareholders who purchased Plug Power shares between January 17, 2025, and November 13, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed as lead plaintiff in the case is April 3, 2026 [3]

ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Picard Medical, Inc. (“Picard” or the “Company”) (NYSE American: PMI). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) Picard was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used ...

ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ: RR). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that Richtech claimed it had a collaborative and commercial relationship with Microsoft when it did not. If you purchased Richtech shares between January 27, 2026 and 12:00 PM EST on January 29, 20 ...